GENERAL
Dr Reddy’s, Nestle Face FSSAI Heat Over Celevida GLP+ Health Claims
The Food Safety and Standards Authority of India (FSSAI) has issued show cause notices to several food business operators and major e-commerce platforms over allegedly misleading advertising and health claims associated with Celevida GLP+, tightening its scrutiny of products positioned around weight management, muscle preservation and GLP-1/GIP therapies. The notices have been issued to Dr […]
CW Bureau
·
Oct 8, 2026
GENERAL
Dr Reddy’s To Distribute Takeda’s QDENGA Dengue Vaccine In India
Dr Reddy’s Laboratories and Takeda Pharmaceutical Company, through its Indian subsidiary Takeda Biopharmaceuticals India Pvt Ltd, have entered into a distribution agreement under which Dr Reddy’s will promote and distribute Takeda’s dengue vaccine QDENGA across India’s private market for pediatric and adult vaccination. Subject to completion of applicable processes with local authorities, QDENGA is expected […]
CW Bureau
·
Sep 18, 2026
GENERAL
Novartis India Terminates Sales Pact With Dr Reddy’s For Key Medicines
Novartis India Ltd has decided to terminate its exclusive distribution and promotion agreement with Dr. Reddy’s Laboratories Ltd (DRL), bringing an end to a strategic partnership signed in 2022 for the marketing and sale of several established medicine brands in India. The company’s Board of Directors has approved the termination of the distribution and promotion […]
Sajan C Kumar
·
Aug 7, 2026
GENERAL
IIMBue 2026 To Bring Together Noel Tata, G V Prasad And Business Titans
As businesses navigate an era shaped by artificial intelligence, geopolitical shifts and rapidly evolving markets, IIMBue 2026, the flagship leadership conclave of the IIM Bangalore Alumni Association (IIMBAA), will bring together some of India’s most influential business and policy leaders to discuss how organisations can redefine growth rather than merely adapt to change. Scheduled for […]
CW Bureau
·
Jul 12, 2026
GENERAL
Dr Reddy’s Oral Semaglutide Brand Obeda For Type 2 Diabetes Launched
Dr Reddy’s Laboratories has launched its oral semaglutide biosimilar for the treatment of Type 2 diabetes mellitus in India under the brand name Obeda, strengthening its presence in the fast-growing GLP-1 therapy segment. The launch follows the company’s recent generic semaglutide injection launches in India and Canada, positioning Dr Reddy’s as a full-stack player in […]
CW Bureau
·
May 20, 2026
GENERAL
Dr Reddy’s Taps Canada’s Diabetes Market With Semaglutide Injection
Dr Reddy’s Laboratories (DRL)has launched its generic Semaglutide injection in Canada, becoming among the first companies to introduce the product in the Canadian market following regulatory approval from Health Canada. The company said it received the Notice of Compliance (NOC) from Health Canada on April 28, 2026, paving the way for the commercial launch. Canada […]
CW Bureau
·
May 16, 2026
GENERAL
Dr Reddy’s Launches Semaglutide Generic Injection For Diabetes Care
Dr Reddy’s Laboratories has announced the launch of Obeda, its injectable Semaglutide, marking a significant milestone in expanding access to advanced GLP-1 receptor agonist therapies for the treatment of type 2 diabetes in India. The company claimed that it is the first Indian player to secure approval from the Drugs Controller General of India (DCGI) […]
CW Bureau
·
Mar 21, 2026
